Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreño AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Seguí E, Brasó-Maristanty F, de la Cruz-Merino L, Juan M, Galván P, Gonzàlez-Farré X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A

Open source

DOI: 10.1038/s41467-026-69222-5
Published: 2026 Feb 16
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-69222-5,
  title = {Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).},
  author = {Pascual T and Vidal M and Cejalvo JM and Vega E and Sanfeliu E and Villacampa G and Ganau S and Parreño AMJ and Zamora E and Miranda I and Delgado A and Bermejo B and Seguí E and Brasó-Maristanty F and de la Cruz-Merino L and Juan M and Galván P and Gonzàlez-Farré X and Chillara S and Villagrasa P and Pfefferle AD and O'Connell CE and Ferrero-Cafiero JM and Oliveira M and Perou CM and Prat A},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-69222-5},
  url = {https://doi.org/10.1038/s41467-026-69222-5}
}

RIS

TY  - JOUR
TI  - Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
AU  - Pascual T
AU  - Vidal M
AU  - Cejalvo JM
AU  - Vega E
AU  - Sanfeliu E
AU  - Villacampa G
AU  - Ganau S
AU  - Parreño AMJ
AU  - Zamora E
AU  - Miranda I
AU  - Delgado A
AU  - Bermejo B
AU  - Seguí E
AU  - Brasó-Maristanty F
AU  - de la Cruz-Merino L
AU  - Juan M
AU  - Galván P
AU  - Gonzàlez-Farré X
AU  - Chillara S
AU  - Villagrasa P
AU  - Pfefferle AD
AU  - O'Connell CE
AU  - Ferrero-Cafiero JM
AU  - Oliveira M
AU  - Perou CM
AU  - Prat A
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-69222-5
UR  - https://doi.org/10.1038/s41467-026-69222-5
ER  -

APA

T, P., M, V., JM, C., E, V., E, S., G, V., S, G., AMJ, P., E, Z., I, M., A, D., B, B., E, S., F, B., L, D. L. C., M, J., P, G., X, G., S, C., P, V., AD, P., CE, O., JM, F., M, O., CM, P., & A, P. (2026). Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).. Nature communications. https://doi.org/10.1038/s41467-026-69222-5

Source records

pubmed · retrieved 2026-09-26T07:13:02.106Z